[HTML][HTML] Discovery and characterization of actionable tumor antigens
G Ehx, C Perreault - Genome medicine, 2019 - Springer
Genome medicine, 2019•Springer
Editorial summary The nature of the tumor antigens that are detectable by T cells remains
unclear. In melanoma, T cells were shown to react against major histocompatibility complex
(MHC)-associated peptides (MAPs) that are derived from exonic mutations. A recent multi-
omic study of hepatocellular carcinomas suggests, however, that mutated exonic MAPs were
exceedingly rare, bringing the accuracy of the current methods for antigen identification into
question and demonstrating the importance of broadening tumor-antigen discovery efforts.
unclear. In melanoma, T cells were shown to react against major histocompatibility complex
(MHC)-associated peptides (MAPs) that are derived from exonic mutations. A recent multi-
omic study of hepatocellular carcinomas suggests, however, that mutated exonic MAPs were
exceedingly rare, bringing the accuracy of the current methods for antigen identification into
question and demonstrating the importance of broadening tumor-antigen discovery efforts.
Editorial summary
The nature of the tumor antigens that are detectable by T cells remains unclear. In melanoma, T cells were shown to react against major histocompatibility complex (MHC)-associated peptides (MAPs) that are derived from exonic mutations. A recent multi-omic study of hepatocellular carcinomas suggests, however, that mutated exonic MAPs were exceedingly rare, bringing the accuracy of the current methods for antigen identification into question and demonstrating the importance of broadening tumor-antigen discovery efforts.
Springer
